SCHEMBL5887283

SCHEMBL5887283

COC1=C(c2ccc(OC)cc2)[CH]CC=C1c1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.42
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PTPN1 P18031 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
ESR2 Q92731 1/20 0.37
APP P05067 1/20 0.36
ABL1 P00519 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887229 0.94 ACHE (0.46) BACE1MAPK1KDM4EMEN1MAPT
SCHEMBL5887134 0.92 ALOX5 (0.39) BACE1MAPK1KDM4EMEN1MAPT
SCHEMBL5887387 0.91 LTA4H (0.51) BACE1KDM4EMEN1MAPTKMT2A
SCHEMBL4007569 0.86 ACHE (0.33) KMT2ANPC1RAB9A
SCHEMBL5887524 0.85 RAD51 (0.37) MAPTCLK4TP53SMN1; SMN2
SCHEMBL5887592 0.82 ABL1 (0.39) BACE1MAPK1KDM4EMAPTKMT2A
SCHEMBL5887251 0.81 BACE1 (0.41) BACE1MAPK1KDM4EMEN1MAPT
SCHEMBL5887421 0.78 LTA4H (0.44) BACE1KDM4EMEN1MAPTKMT2A
SCHEMBL5887293 0.77 LTA4H (0.50) BACE1KDM4EMEN1MAPTKMT2A
SCHEMBL5887317 0.76 ALOX5 (0.39) BACE1MAPK1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R BACE1 944/4885MAPK1 305/4885KDM4E 3706/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R BACE1 1420/4885MAPK1 339/4885KDM4E 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.